We think a delay rather than an outright rejection for this company’s product is the likelier outcome, but the shares still look expensive.

Niche play with more growth potential than many investors give it credit for.

The market cheers update from the company.

The company is poised to take advantage of clear overarching macro revenue drivers.

The global education services provider has gone from stock market darling to one of the ASX's weakest performers. What gives?

Turmoil with the board culuminates in the departure of the CEO.

A sound business model but the shares are expensive.

Road to profitability is in sight as management continues to take the right steps.

The ASX's biggest healthcare name saw its shares fall after reporting first-half results.

Solid device sales with shares moderately undervalued.